NCT06043674 - A Ph2 Study of Glofitamab Alone or With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 22, 2024

Primary Completion Date

January 15, 2028

Study Completion Date

January 15, 2033

Conditions

Chronic Lymphocytic LeukemiaRichter's Transformation

Interventions

DRUG

Glofitamab

"2:1 T-cell bispecific humanized monoclonal antibody, administered via intravenous infusion per protocol."

DRUG

Obinutuzumab

Humanized glycoengineered type II anti-CD20 monoclonal antibody, administered via intravenous infusion per protocol.

DRUG

Polatuzumab Vedotin

Antibody-drug conjugate, administered via intravenous infusion per protocol.

DRUG

Atezolizumab

Humanized immunoglobulin monoclonal antibody, administered via intravenous infusion per protocol.

DRUG

Tocilizumab

For the treatment of Cytokine Release Syndrome. Recombinant, humanized, anti-human monoclonal antibody, administered via intravenous infusion per protocol.

DRUG

Pirtobrutinib

Selective inhibitor of BTK, 50 mg or 100 mg tablet, via oral administration per protocol.

Trial Locations (4)

27599

RECRUITING

The University of North Carolina at Chapel Hill, Chapel Hill

43210

RECRUITING

The Ohio State University Wexner Medical Center, Columbus

02215

RECRUITING

Brigham and Women's Hospital, Boston

RECRUITING

Dana Farber Cancer Institute, Boston